Suppr超能文献

捍卫社会主权:对尼曼《成本效用分析中纳入幸存者消费》的评论

In defence of societal sovereignty: a comment on Nyman 'the inclusion of survivor consumption in CUA'.

作者信息

Richardson Jeffrey R J, Olsen Jan Abel

机构信息

Centre for Health Economics, Monash University, Australia.

出版信息

Health Econ. 2006 Mar;15(3):311-3; discussion 319-22. doi: 10.1002/hec.1066.

Abstract

Whether to include or exclude consumption costs and costs of unrelated illnesses in economic evaluation is not a technical issue which may be answered by reference to individuals alone and the consistency of the treatment of individual costs and benefits. In the context of a publicly funded health service the relevant costs and benefits may differ from those normally included in evaluation studies. Specifically, the social welfare function is likely to exclude benefits which would result in preferential care for wealthier members of society. But this conclusion must be established by analysis of social, not individual, values.

摘要

在经济评估中是否纳入消费成本和无关疾病的成本,这并非一个仅通过参考个体以及个体成本与收益处理的一致性就能回答的技术问题。在公共资助的医疗服务背景下,相关成本和收益可能与评估研究中通常纳入的有所不同。具体而言,社会福利功能可能会排除那些会导致对社会中较富裕成员给予优先照顾的收益。但这一结论必须通过对社会价值而非个体价值的分析来确立。

相似文献

1
In defence of societal sovereignty: a comment on Nyman 'the inclusion of survivor consumption in CUA'.
Health Econ. 2006 Mar;15(3):311-3; discussion 319-22. doi: 10.1002/hec.1066.
2
On the lottery equivalents method: a response to Spencer et al.
Health Econ. 2006 Mar;15(3):323-5. doi: 10.1002/hec.1094.
3
Consumption costs and earnings during added years of life - a reply to Nyman.
Health Econ. 2006 Mar;15(3):315-7; discussion 319-22. doi: 10.1002/hec.1065.
4
Welfare, QALYs, and costs - a comment.
Health Econ. 2011 Jan;20(1):68-72. doi: 10.1002/hec.1600.
5
Theory and methods of economic evaluation of health care.
Dev Health Econ Public Policy. 1996;4:1-245.
7
Discounting in health care decision-making: time for a change?
J Public Health Med. 1992 Sep;14(3):250-6.
8
On the possibility of a bridge between CBA and CEA: comments on a paper by Dolan and Edlin.
J Health Econ. 2004 Sep;23(5):887-98. doi: 10.1016/j.jhealeco.2003.10.002.
9
A note on cost-value analysis.
Health Econ. 2003 Mar;12(3):247-50; discussion 251-3. doi: 10.1002/hec.719.
10
Should the consumption of survivors be included as a cost in cost-utility analysis?
Health Econ. 2004 May;13(5):417-27. doi: 10.1002/hec.850.

引用本文的文献

1
Incorporating future unrelated medical costs in cost-effectiveness analysis in China.
BMJ Glob Health. 2021 Oct;6(10). doi: 10.1136/bmjgh-2021-006655.
2
Future Costs in Cost-Effectiveness Analyses: Past, Present, Future.
Pharmacoeconomics. 2019 Feb;37(2):119-130. doi: 10.1007/s40273-018-0749-8.
4
Pharmacoeconomic guidelines should prescribe inclusion of indirect medical costs! A response to Grima et Al.
Pharmacoeconomics. 2013 May;31(5):369-73; discussion 375-6. doi: 10.1007/s40273-013-0042-9.

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验